Program
Adjuvant
Also written as “Monovalent Avian Influenza VLP (H5N1); Adjuvant”, “Matrix-M2 Adjuvant (25μg)” and “Matrix-M2 Adjuvant (50μg)”.
Its studies are mostly in Influenza, Human · Herpes Simplex · Herpes Zoster · Malaria · Respiratory Syncytial Virus Infections, led by 11 companies.
Drug pageAdjuvant: every studyMany companies study it; this page follows only the 15 they lead. All 21 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Genocea Biosciencesits history only | 30 open or running | phase 2since Apr 11, 2014 | Nov 19, 2013 | none ahead |
| BioTech Toolsits history only | 20 open or running | phase 2since Dec 7, 2011 | Apr 20, 2010 | none ahead |
| Novavaxits history only | 20 open or running | phase 1since May 2, 2012 | May 2, 2012 | none ahead |
| Colby Pharmaceuticalits history only | 10 open or running | phase 1since Apr 15, 2008 | Apr 15, 2008 | none ahead |
| Guangzhou Patronus Biotechits history only | 11 open or running | phase 1since May 28, 2024 | May 28, 2024 | none ahead |
| Immune Targeting Systemsits history only | 10 open or running | phase 1since Oct 3, 2012 | Oct 3, 2012 | none ahead |
| MAXVAX Biotechnology Limited Liabilityits history only | 10 open or running | phase 1since Nov 16, 2022 | Nov 16, 2022 | none ahead |
| Medigen Vaccine Biologicsits history only | 10 open or running | phase 2since Apr 27, 2015 | Apr 27, 2015 | none ahead |
| Sanofiits history only | 10 open or running | phase 1since Jun 25, 2020 | Jun 25, 2020 | none ahead |
| Serum Institute of India Pvt.its history only | 11 open or running | phase 2since Aug 12, 2025 | Aug 12, 2025 | Nov 2027phase 2 · NCT07147400 |
| Yikang Biotech (Suzhou)its history only | 11 open or running | phase 1since Sep 1, 2026 | Sep 1, 2026 | Jan 22, 2027phase 1 · NCT07807449 |
Also a collaborator on its studies: Yantai Patronus Biotech.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 15, 2008First study: phase 1 study in Influenza, HumanNew to Colby PharmaceuticalColby Pharmaceutical · NCT00662272 · 128 enrolled · United States
- Apr 20, 2010BioTech Tools’ first study: phase 1 study in Seasonal Allergic RhinoconjunctivitisNew to BioTech ToolsBioTech Tools · NCT01111279 · 27 enrolled · Belgium
- Dec 7, 2011Phase 2 study in Rhinitis, Allergic, SeasonalBioTech Tools · NCT01506375 · 24 enrolled · Belgium
- May 2, 2012Novavax’s first studies: 2 phase 1 studies in Influenza, HumanNew to NovavaxNovavax · NCT01594320, NCT01596725
- Oct 3, 2012Immune Targeting Systems’ first study: phase 1 study in Influenza ANew to Immune Targeting SystemsImmune Targeting Systems · NCT01701752 · 120 enrolled
- Nov 19, 2013Genocea Biosciences’ first study: phase 1 study in Streptococcus PneumoniaeNew to Genocea BiosciencesGenocea Biosciences · NCT01995617 · 90 enrolled · United States
- Apr 11, 2014Phase 2 study in Herpes SimplexGenocea Biosciences · NCT02114060 · 310 enrolled · United States
- Nov 20, 2014Phase 2 study in Herpes SimplexGenocea Biosciences · NCT02300142 · 37 enrolled · United States
- Apr 27, 2015Medigen Vaccine Biologics’ first study: phase 2 study in H7N9 Influenza VaccineNew to Medigen Vaccine BiologicsMedigen Vaccine Biologics · NCT02436928 · 200 enrolled · Taiwan
- Jun 25, 2020Sanofi’s first study: phase 1 study in Influenza, HumanNew to SanofiSanofi · NCT04451954 · 210 enrolled · United States
- Nov 16, 2022MAXVAX Biotechnology Limited Liability’s first study: phase 1 study in Herpes ZosterNew to MAXVAX Biotechnology Limited LiabilityMAXVAX Biotechnology Limited Liability · NCT05636436 · 132 enrolled · China
- May 28, 2024Guangzhou Patronus Biotech’s first study: phase 1 study in Respiratory Syncytial Virus InfectionsNew to Guangzhou Patronus BiotechGuangzhou Patronus Biotech · NCT06442241 · 84 enrolled · Australia
- Aug 12, 2025Serum Institute of India Pvt.’s first study: phase 2 study in Prevention of Malaria Transmission and Clinical MalariaNew to Serum Institute of India Pvt.Serum Institute of India Pvt. · NCT07147400 · 1,200 enrolled · Mali
- Sep 1, 2026Yikang Biotech (Suzhou)’s first study: phase 1 study in Respiratory Syncytial Virus (RSV)New to Yikang Biotech (Suzhou)Yikang Biotech (Suzhou) · NCT07807449 · 128 planned · China
Ahead
- Jan 22, 2027Primary completion: phase 1 study in Respiratory Syncytial Virus (RSV)Yikang Biotech (Suzhou) · NCT07807449
- Nov 2027Primary completion: phase 2 study in Prevention of Malaria Transmission and Clinical MalariaSerum Institute of India Pvt. · NCT07147400
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07807449Respiratory Syncytial Virus (RSV) · China | 1 | Not yet recruiting | Yikang Biotech (Suzhou) | Jan 22, 2027 | 128 |
| NCT07147400Prevention of Malaria Transmission and Clinical Malaria · Mali | 2 | Active, not recruiting | Serum Institute of India Pvt. | Nov 2027 | 1,200 |
| NCT06442241Respiratory Syncytial Virus Infections · Australia | 1 | Active, not recruiting | Guangzhou Patronus Biotech | Dec 30, 2025 | 84 |
| NCT05636436Herpes Zoster · China | 1 | Completed | MAXVAX Biotechnology Limited Liability | May 23, 2025 | 132 |
| NCT04451954Influenza, Human · United States | 1 | Completed | Sanofi | Sep 20, 2021 | 210 |
| NCT02436928H7N9 Influenza Vaccine · Taiwan | 2 | Completed | Medigen Vaccine Biologics | Feb 2016 | 200 |
| NCT02300142Herpes Simplex · United States | 2 | Completed | Genocea Biosciences | Jun 2016 | 37 |
| NCT02114060Herpes Simplex · United States | 2 | Completed | Genocea Biosciences | Feb 2016 | 310 |
| NCT01995617Streptococcus Pneumoniae · United States | 1 | Completed | Genocea Biosciences | Feb 2015 | 90 |
| NCT01701752Influenza A | 1 | Completed | Immune Targeting Systems | Apr 2013 | 120 |
| NCT01596725Influenza, Human · United States | 1 | Completed | Novavax | Aug 2012 | 333 |
| NCT01594320Influenza, Human · United States | 1 | Completed | Novavax | Jul 2012 | 333 |
| NCT01506375Rhinitis, Allergic, Seasonal · Belgium | 2 | Completed | BioTech Tools | Jan 2013 | 24 |
| NCT01111279Seasonal Allergic Rhinoconjunctivitis · Belgium | 1 | Completed | BioTech Tools | Sep 2010 | 27 |
| NCT00662272Influenza, Human · United States | 1 | Completed | Colby Pharmaceutical | Oct 2008 | 128 |
How it is read
Names in the registry
- “Monovalent Avian Influenza VLP (H5N1); Adjuvant”, 6 entries
- “Matrix-M2 Adjuvant (25μg)”, 2 entries
- “Matrix-M2 Adjuvant (50μg)”, 2 entries
- “Matrix-M2 Adjuvant (75μg)”, 2 entries
- “Low dose adjuvant”, 1 entry
Conditions, from the studies’ own filings
- Influenza, Human, 6 studies
- Herpes Simplex, 2 studies
- Herpes Zoster, 1 study
- Malaria, 1 study
- Respiratory Syncytial Virus Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.